The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $218,370.00 firm fixed-price delivery order contract to Mayo Clinic, a large non-profit academic medical center, for "Pharmacokinetic Studies with Selected Anticancer Compounds in NSG Mice." The period of performance is September 13, 2019 through September 12, 2024. This delivery order is issued under the Pharmacokinetic and Pharmacology Evaluations for Cancer Patients...
This is a firm-fixed price delivery order awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Mayo Clinic, a renowned non-profit academic medical center. The contract is for $1,603.00 and covers pre-clinical pharmacokinetic and pharmacology evaluations of cancer therapeutic agents being developed under the NCI's Experimental Therapeutics program. This work supports the transition of promising cancer treatments from the laboratory to early...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a delivery order contract worth $3,665,424.78 to the Mayo Clinic, a large non-profit academic medical center focused on integrated clinical practice, education, and research. The contract is to provide core infrastructure support for the Cancer Prevention Agent Development Program's Early Phase Clinical Research efforts. This award is not a set-aside contract. Mayo Clinic has extensive...
This federal contract award, valued at $259,490.16, was issued by the National Cancer Institute (NCI) to Mayo Clinic, a renowned non-profit academic medical center. The contract provides "Core Infrastructure Support" and is classified as a Delivery Order with a Cost No Fee pricing type. The award does not have a set-aside designation. Mayo Clinic holds a multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the NCI, valued at up to $9.9 million, to provide...
This federal contract award, valued at $1,070.00, was issued by the National Cancer Institute (NCI) to Mayo Clinic, a renowned non-profit academic medical center, to provide contract orientation and kick-off meeting support for an Indefinite Delivery/Indefinite Quantity (IDIQ) contract titled "Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients." The contract is structured as a firm-fixed price delivery order and does not have a...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a delivery order contract to Mayo Clinic, a large non-profit academic medical center, to provide core infrastructure support services. The $658,179.00 contract does not have a set-aside designation and is part of the Cancer Prevention Agent Development Program: Early Phase Clinical Research major program. Mayo Clinic will implement bioanalytical methods, conduct pharmacokinetic...
Mayo Clinic was awarded a cost-plus-fixed-fee delivery order against its indefinite delivery/indefinite quantity contract with the National Cancer Institute. The $1,996,069 order has a period of performance through July 2023 to support preclinical pharmacokinetic evaluations for the National Cancer Institute's Experimental Therapeutics program in Rochester, Minnesota. No set-aside designation was used for this order to further the agency's aim of aiding the development and approval of new cancer...
This is a firm-fixed price delivery order awarded by the National Cancer Institute (NCI) to Mayo Clinic, a renowned non-profit academic medical center. The contract, with a ceiling value of $76,500.00, supports the NCI's Cancer Genome Atlas (TCGA) program by providing tissue samples and data from various types of cancer. This order is part of a larger $9.9 million indefinite delivery/indefinite quantity (IDIQ) contract awarded to Mayo Clinic in 2021, which enables the NCI to procure research and...
This federal contract award is to Mayo Clinic, a large non-profit academic medical center, for a randomized, double-blind, placebo-controlled clinical trial of a MUC1 vaccine in patients with newly diagnosed advanced adenoma. The contract was awarded by the National Cancer Institute, part of the National Institutes of Health, and is funded under the Cancer Prevention Agent Development Program for early-phase clinical research. The contract has a total ceiling value of $89,746.31 and was...
This is a delivery order awarded by the Defense Advanced Research Projects Agency (DARPA) to Mayo Clinic, a non-profit academic medical center, for R&D services under task order 0013. The cost-plus-fixed-fee contract has a ceiling value of $963,140.00 and a period of performance ending on October 15, 2016. Mayo Clinic, which is registered in SAM.gov as a private university, hospital, non-profit organization, and educational institution, has provided a wide range of biomedical research,...
This is a delivery order awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to Mayo Clinic, a large non-profit academic medical center. The five-year, $204,622.95 contract supports pharmacokinetic and bioavailability studies of selected anticancer compounds in mice, which will provide analytical support to the NCI's Experimental Therapeutics program. Mayo Clinic is conducting these preclinical evaluations under a larger $9.9 million multiple-award indefinite delivery/indefinite quantity (IDIQ) contract with the NCI, awarded in 2021. This IDIQ contract enables the NCI to efficiently access Mayo Clinic's cancer research and drug development expertise over multiple years. The current delivery order does not have a set-aside designation, reflecting Mayo Clinic's status as a large institution.